PMID- 18558584
OWN - NLM
STAT- MEDLINE
DCOM- 20080916
LR  - 20211020
IS  - 1699-048X (Print)
IS  - 1699-048X (Linking)
VI  - 10
IP  - 6
DP  - 2008 Jun
TI  - Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in 
      epithelial ovarian carcinoma.
PG  - 367-71
AB  - OBJECTIVE: The role of molecular and biological factors in ovarian cancer is 
      controversial. We investigated the levels of the estrogen (ER) and progesterone 
      (PR) receptors, HER2/neu, p-53 and Ki 67 in patients with advanced ovarian cancer 
      and correlated the results with the clinical course in order to define their 
      predictive or prognostic significance. METHODS: Paraffin-embedded tumor tissues 
      from 72 patients with ovarian cancer treated from 1999 to 2003 were analyzed. 
      Overexpression of C-erb-B2 was defined as herceptest ++/+++ and positive 
      fluorescence in situ hybridization (FISH) or herceptest +++/+++. Positivity for 
      ER and PR was determined by > or =10% of the cellular membranes immunostained. 
      Statistical analysis was performed to evaluate the prognostic impact of the 
      molecular markers. RESULTS: 49 of the 72 patients were ER + (68%) and 36 PR + 
      (50%). In 45 patients (62.5%) expression of p53 was > or =10%. Overexpression of 
      C-erb-2 was found in 4 tumor samples (5%). A Ki67 labelled nuclear area >30% was 
      found to be associated with a higher rate of complete response (chi(2); p=0.05). 
      None of the biological markers were significantly associated with progression 
      free survival (PFS). By multivariate analysis residual tumor after debulking 
      surgery and ER status were associated with OS (p< or =0.05). CONCLUSIONS: Ki67 
      nuclear expression >30% is predictive of complete response in advanced ovarian 
      cancer. HER2/neu overexpression is scarce in our study. Positive ER is an 
      independent prognostic factor for OS. Further research with larger studies and 
      hormonal treatment is guaranteed.
FAU - Garcia-Velasco, A
AU  - Garcia-Velasco A
AD  - Division of Medical Oncology, Institut Catala d'Oncologia, Hospital Universitario 
      Dr. Josep Trueta, Girona, Spain. agvelasco@ico.scs.es
FAU - Mendiola, C
AU  - Mendiola C
FAU - Sanchez-Munoz, A
AU  - Sanchez-Munoz A
FAU - Ballestin, C
AU  - Ballestin C
FAU - Colomer, R
AU  - Colomer R
FAU - Cortes-Funes, H
AU  - Cortes-Funes H
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Ki-67 Antigen/biosynthesis
MH  - Middle Aged
MH  - Neoplasms, Glandular and Epithelial/*metabolism/mortality
MH  - Ovarian Neoplasms/*metabolism/mortality
MH  - Prognosis
MH  - Receptor, ErbB-2/biosynthesis
MH  - Receptors, Estrogen/biosynthesis
MH  - Receptors, Progesterone/biosynthesis
MH  - Tumor Suppressor Protein p53/biosynthesis
EDAT- 2008/06/19 09:00
MHDA- 2008/09/17 09:00
CRDT- 2008/06/19 09:00
PHST- 2008/06/19 09:00 [pubmed]
PHST- 2008/09/17 09:00 [medline]
PHST- 2008/06/19 09:00 [entrez]
AID - CLAT34 [pii]
AID - 10.1007/s12094-008-0213-x [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2008 Jun;10(6):367-71. doi: 10.1007/s12094-008-0213-x.